Bimagrumab to Prevent Semaglutide-Induced Lean Mass Loss in DIO Mice
- Lean mass loss induced by GLP1R agonists is emerging as a critical challenge in obesity management
- Bimagrumab is in clinical development to address lean mass loss with GLP1R agonist therapies
- Bimagrumab protects against lean mass loss while maintaining semaglutide’s weight loss efficacy in DIO mice